Effects of anti-IL-23 and anti-IL-17: The hidden side of spondyloarthritis polymorphism?

[1]  C. Prati,et al.  Vascular involvement in axial spondyloarthropathies. , 2019, Joint, bone, spine : revue du rhumatisme.

[2]  Ahmed M. Mehdi,et al.  IL-23 favours outgrowth of spondyloarthritis-associated pathobionts and suppresses host support for homeostatic microbiota , 2019, Annals of the rheumatic diseases.

[3]  L. Rogge,et al.  Expansion of Interleukin‐22– and Granulocyte–Macrophage Colony‐Stimulating Factor–Expressing, but Not Interleukin‐17A–Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With Spondyloarthritis , 2019, Arthritis & rheumatology.

[4]  D. Heijde,et al.  Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis , 2018, Arthritis & rheumatology.

[5]  C. Prati,et al.  Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis , 2018, Expert opinion on biological therapy.

[6]  J. Berthelot,et al.  Translocation of dead or alive bacteria from mucosa to joints and epiphyseal bone-marrow: facts and hypotheses. , 2019, Joint, bone, spine : revue du rhumatisme.

[7]  I. McInnes,et al.  Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation? , 2018, Annals of the rheumatic diseases.

[8]  D. Baeten,et al.  The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling , 2018, Front. Immunol..

[9]  Tae-Hwan Kim,et al.  Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study , 2018, Annals of the rheumatic diseases.

[10]  M. Dougados,et al.  2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. , 2018, Joint, bone, spine : revue du rhumatisme.

[11]  C. Prati,et al.  Spondyloarthritis: An expanding cast of cellular actors. , 2018, Joint, bone, spine : revue du rhumatisme.

[12]  M. Dougados,et al.  Two Phenotypes Are Identified by Cluster Analysis in Early Inflammatory Back Pain Suggestive of Spondyloarthritis: Results From the DESIR Cohort , 2016, Arthritis & rheumatology.

[13]  D. Wendling.  The gut in spondyloarthritis. , 2016, Joint, bone, spine : revue du rhumatisme.

[14]  M. Dougados,et al.  Spondyloarthritis: A concept or a disease? , 2015, Joint, bone, spine : revue du rhumatisme.

[15]  D. Wendling,et al.  Spondyloarthritis: Criteria, limitations, and perspectives throughout history. , 2015, Joint, bone, spine : revue du rhumatisme.

[16]  D. Wendling.  Involvement of Th 17 pathway in spondyloarthritis. , 2015, Bulletin de l'Academie nationale de medecine.

[17]  C. Prati,et al.  The IL-23/Th 17 pathway in spondyloarthritis: the royal road? , 2015, Joint, bone, spine : revue du rhumatisme.

[18]  M. Neurath,et al.  How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy , 2013, Nature Medicine.

[19]  M. Dougados,et al.  Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what's in a name? , 2012, Joint, bone, spine : revue du rhumatisme.

[20]  Marc Vandemeulebroecke,et al.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.

[21]  C. Tripodo,et al.  Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. , 2009, Arthritis and rheumatism.

[22]  R. Porcher,et al.  Two major spondylarthropathy phenotypes are distinguished by pattern analysis in multiplex families. , 2005, Arthritis and rheumatism.